Randomised trials suggest that ximelagatran is “non-inferior” to warfarin for preventing stroke in patients with non-valvular atrial fibrillation, but important questions remain
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Hart RG, Halperin JL, Pearce LA, et al. Lessons from the Stroke Prevention in Atrial Fibrillation Trials. Ann Intern Med 2003; 138: 831-838.
- 2. Lake FR, Cullen KJ, de Klerk NH, et al. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med 1989; 19: 321-326.
- 3. Thrift AG, Dewey HM, Macdonell RAL, et al. Incidence of the major stroke subtypes: initial findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2001; 32: 1732-1738.
- 4. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
- 5. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119 (1 Suppl); 8S-21S.
- 6. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomised trials translate into clinical practice? JAMA 2003; 290: 2685-2692.
- 7. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality. N Engl J Med 2003; 349: 1019-1026.
- 8. SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor Ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-1698.
- 9. The Executive Steering Committee on behalf of the SPORTIF V investigators. Stroke prevention using the oral direct thrombin inhibitor Ximelagatran in patients with nonvalvular atrial fibrillation (SPORTIF V). Late-breaking clinical trial abstracts [abstract]. Circulation 2003; 108: 2.
- 10. Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003; 146: 431-438.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Graeme Hankey is a member of the Steering Committee of the AMADEUS trial, the Stroke Advisory Committee of the ACTIVE trial, and the Atrial Fibrillation Advisory Board for Exanta, AstraZeneca, Australia.